Finance

Lists
1177:HKG
Sino Biopharmaceutical Ltd
5,25 HK$
-0,38%
(-0,020) 1D
16 հոկ, 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 1177...
Open
5,40 HK$
High
5,50 HK$
Low
5,14 HK$
Mkt. cap
98,09 մլրդ
Avg. vol.
69,33 մլն
Volume
83,88 մլն
Dividend
2,29%
Quarterly dividend
0,03 HK$
Ex-dividend date
29 օգս, 2025 թ.
P/E ratio
33,86
52-wk high
7,79 HK$
52-wk low
4,19 HK$
EPS
0,16 HK$
Shares outstanding
12,64 մլրդ
No. of employees
23 հզր
Open
5,40 HK$
High
5,50 HK$
Low
5,14 HK$
Mkt. cap
98,09 մլրդ
Avg. vol.
69,33 մլն
Volume
83,88 մլն
Dividend
2,29%
Quarterly dividend
0,03 HK$
Ex-dividend date
29 օգս, 2025 թ.
P/E ratio
33,86
52-wk high
7,79 HK$
52-wk low
4,19 HK$
EPS
0,16 HK$
Shares outstanding
12,64 մլրդ
No. of employees
23 հզր
News stories
From web sources and news partners
Profile
Sino Biopharmaceutical Limited, shortly SBP Group, is a pharmaceutical conglomerate in China. The Company was listed on the Hong Kong Stock Exchange in 2000 and included in 2013 as a constituent stock of MSCI Global Standard Indices – MSCI China Index, Hang Seng Index in 2018, Hang Seng China Enterprises Index in 2019, and Hang Seng Connect Biotech 50 Index and Hang Seng China 25 Index in 2020. The Group’s principal subsidiaries include: Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Beijing Tide Pharmaceutical Co. Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Jiangsu Chia Tai Qingjiang Pharmaceutical Co., Ltd. and invoX Pharma Limited. Its products including biopharmaceutical and chemical medicines are used in a host of therapeutic areas, such as tumors, liver diseases, respiratory system diseases and surgery/analgesia. Wikipedia
About Sino Biopharmaceutical Ltd
CEOLi Yi
Employees22,8 հզր
Founded2000
Headquarters-
Sector-
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
7,13 մլրդ
7,13 մլրդ
9,72 մլրդ
9,72 մլրդ
Cost of goods sold
1,31 մլրդ
1,31 մլրդ
1,65 մլրդ
1,65 մլրդ
Cost of revenue
1,31 մլրդ
1,31 մլրդ
1,65 մլրդ
1,65 մլրդ
Research and development expenses
2,93 մլրդ
2,93 մլրդ
1,54 մլրդ
1,54 մլրդ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,80 մլրդ
2,80 մլրդ
3,11 մլրդ
3,11 մլրդ
Operating expense
4,38 մլրդ
4,38 մլրդ
4,77 մլրդ
4,77 մլրդ
Total operating expenses
5,69 մլրդ
5,69 մլրդ
6,42 մլրդ
6,42 մլրդ
Operating income
1,44 մլրդ
1,44 մլրդ
3,31 մլրդ
3,31 մլրդ
Other non operating income
97,99 մլն
97,99 մլն
76,64 մլն
76,64 մլն
EBT including unusual items
488,22 մլն
488,22 մլն
3,67 մլրդ
3,67 մլրդ
EBT excluding unusual items
1,55 մլրդ
1,55 մլրդ
3,56 մլրդ
3,56 մլրդ
Income tax expense
323,77 մլն
323,77 մլն
597,96 մլն
597,96 մլն
Effective tax rate
66,32%
66,32%
16,29%
16,29%
Other operating expenses
-1,35 մլրդ
-1,35 մլրդ
113,21 մլն
113,21 մլն
Net income
-522,62 մլն
-522,62 մլն
1,72 մլրդ
1,72 մլրդ
Net profit margin
-7,33%
-7,33%
17,66%
17,66%
Earnings per share
-
-
-
-
Interest and investment income
196,36 մլն
196,36 մլն
250,06 մլն
250,06 մլն
Interest expense
-77,56 մլն
-77,56 մլն
-84,75 մլն
-84,75 մլն
Net interest expenses
118,80 մլն
118,80 մլն
165,31 մլն
165,31 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
1,66 մլրդ
1,66 մլրդ
3,57 մլրդ
3,57 մլրդ
Gain or loss from assets sale
-5,58 մլն
-5,58 մլն
-
-
AI content may include mistakes. Learn more
Google Apps